Empagliflozin and Other SGLT2 Inhibitors Show Cardioprotective Benefits
Since the landmark EMPA-REG OUTCOME trial, sodium–glucose cotransporter 2 (SGLT2) inhibitors have rapidly shifted from diabetes drugs to a central ...
Tag: diabetes and kidney disease therapies
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!